Drug Trial Radar · NCT07109375
Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting
Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Jun 15, 2026
Primary completion
Feb 2029
Study completion Feb 2029
Sponsor
- Lead sponsor
- Chiesi ItaliaIndustry
- Sponsor type
- Industry
- First posted
- Aug 7, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PEGASO is an observational study designed to collect prospective data on the effectiveness and safety of pegunigalsidase alfa in adult patients with Fabry disease, being treated or planning to start treatment, under real-world setting.
Conditions
- Fabry Disease
Interventions
pegunigalsidase alfaDrug
Pegunigalsidase alfa is 2 mg/mL concentrate for solution and is administered via intravenous infusion every two weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of structural abnormalities of the left ventricleTime frame: 24 months
- Assessment of left ventricular diastolic functionTime frame: 12 and 24 months
- Assessment of renal functionTime frame: 6, 12, 18 and 24 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
AUSL Toscana Sud-Est - Ospedale San Donato
Arezzo, Italy · Not yet recruiting
Azienda Ospedaliera Universitaria Consorziale Policlinico Di Bari
Bari, Italy · Recruiting
Irccs Azienda Ospedaliero-Universitaria Di Bologna - Policlinico Di Sant'Orsola
Bologna, Italy · Recruiting
A.O. Sant'Anna e San Sebastiano
Caserta, Italy · Not yet recruiting
U.O.C. Nefrologia ASST Monza - Ospedale San Gerardo
Monza, Italy · Not yet recruiting
AOU Federico II, Dipartimento di Nefrologia
Naples, Italy · Not yet recruiting
A.O.U. Policlinico "Giaccone"
Palermo, Italy · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.